Idrx - Crunchbase Company Profile & Funding

Q: Where is Idrx's headquarters?

Idrx is located in Cambridge, Massachusetts, United States.

Q: Who invested in Idrx?

Idrx has 10 investors including Nextech Invest And Andreessen Horowitz.

Q: When was the last funding round for Idrx?

Idrx closed its last funding round on obfuscated from a Series B round.

Overview

Idrx

Total Funding

obfuscation

Growth Score

Heat Score

Company Performance Metrics

Score

Trend

About These Metrics

AI Content may contain mistakes and is not legal, financial or investment advice.

Learn more.

Growth Score - The measure of growth based on company activity, operational metrics, and investments

Growth Trend - The change in the growth score over the given time period

Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity

Heat Trend - The change in the heat score over the given time period

Recent Milestones

Raised Funding Round

Jan 1, 1970

Lorem ipsum dolor sit amet, consectetur

See more interactive data and historical milestones on desktop for the best experience

About Idrx

CB Rank

17103

Idrx is a clinical-stage biopharmaceutical that develops oncology-based precision therapies to treat cancer.

Acquired by

GlaxoSmithKline

Founded

obfuscation

Private

Series B

Cambridge, Massachusetts, United States

11-50

www.idrx.com/

Biotechnology

Life Science

Oncology

Product Research

Funding Rounds

Series B

OBF

obfuscation

Series A

OBF

obfuscation

Key People

Ben Auspitz: Co-Founder and CEO
Past Role: F-Prime, Partner
Alexis Borisy: Co-Founder
Past Role: EQRx, Co-Founder, Chairman, and CEO

Details

Legal Name

Idrx Inc

Operating Status

Active

Company Type

For Profit

Founders

Alexis Borisy, Ben Auspitz, George Demetri, Nick Lydon, Robert Forrester

About the Company

Idrx is a clinical-stage biopharmaceutical that develops oncology-based precision therapies to treat gastrointestinal stromal tumors. It designs precision combination therapies, medicines with engineered drug combinations to stop key tumor escape mechanisms and prolong response to therapy.

Contact Email

info@Idrx.com

Predictions & Insights

Growth Insight

See this Growth Insight

Idrx is

Lorem

to be growing

Top Contributing Factors

Recently Raised Funding

Growth Prediction

See this Growth Prediction

Top Contributing Factors

Key Employee Changes

Products & Services

IDRX-42

An oral, selective KIT inhibitor targeting activating and resistance mutations in KIT-mutant gastrointestinal stromal tumors (GIST).

IDRX-73

A selective inhibitor targeting exon-13-mutant KIT for potential treatment of KIT-mutant gastrointestinal stromal tumors.

Research & Development

Idrx is

obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated

...

Unlock More with Crunchbase Pro

Full access to financial & funding data on unlimited profiles
Export up to 2k results/month for analysis
Track market signals on competitors, products, and R&D
Preview private company insights and predictions

Financials

Company Funding

Funding Rounds

Investors

Total Funding Amount

obfuscation

Number of Funding Rounds

Unlock company funding data, including rounds, dates, amounts, and investors.

Announced Date	Transaction Name	Number of Investors	Money Raised	Lead Investors	Funding Type
obfuscated obfuscation	Series B - Idrx	10	obfuscated obfuscation	Blackstone Group, Commodore Capital, RA Capital Management	Series B
obfuscated obfuscation	Series B - Idrx	10	obfuscated obfuscation	Blackstone Group, Commodore Capital, RA Capital Management	Series B
obfuscated obfuscation	Series B - Idrx	10	obfuscated obfuscation	Blackstone Group, Commodore Capital, RA Capital Management	Series B
obfuscated obfuscation	Series B - Idrx	10	obfuscated obfuscation	Blackstone Group, Commodore Capital, RA Capital Management	Series B
obfuscated obfuscation	Series B - Idrx	10	obfuscated obfuscation	Blackstone Group, Commodore Capital, RA Capital Management	Series B

Funding Rounds

Total Funding Amount

obfuscation

Number of Funding Rounds

Unlock company funding data, including rounds, dates, amounts, and investors.

Announced Date	Transaction Name	Number of Investors	Money Raised	Lead Investors	Funding Type
obfuscated obfuscation	Series B - Idrx	10	obfuscated obfuscation	Blackstone Group, Commodore Capital, RA Capital Management	Series B
obfuscated obfuscation	Series B - Idrx	10	obfuscated obfuscation	Blackstone Group, Commodore Capital, RA Capital Management	Series B
obfuscated obfuscation	Series B - Idrx	10	obfuscated obfuscation	Blackstone Group, Commodore Capital, RA Capital Management	Series B
obfuscated obfuscation	Series B - Idrx	10	obfuscated obfuscation	Blackstone Group, Commodore Capital, RA Capital Management	Series B
obfuscated obfuscation	Series B - Idrx	10	obfuscated obfuscation	Blackstone Group, Commodore Capital, RA Capital Management	Series B

Investors

Unlock company funding data, including rounds, dates, amounts, and investors.

Investor Name	Lead Investor	Funding Round	Partners
Nextech Invest	—	Series B - Idrx	—
Nextech Invest	—	Series B - Idrx	—
Nextech Invest	—	Series B - Idrx	—
Nextech Invest	—	Series B - Idrx	—
Nextech Invest	—	Series B - Idrx	—